Content in this section will include AAPM advocacy efforts, legislative news, public statements, etc.

FDA MedWatch Safety Alert: RXQ Compounding, LLC Issues Voluntary Nationwide Recall of All Sterile Products

 RXQ Compounding, LLC ("RXQ") is voluntarily recalling all sterile human and animal products within expiry to the user level due to lack of sterility process assurance associated with the production of the Company's...
Continue reading
Topics:
FDA

AMA Opioid Task Force Recommendations Offer Roadmap to Policymakers

The recommendations include tangible actions policymakers can take to help reduce barriers to evidence-based treatment and end the nation's opioid epidemic. AAPM is among the 25 specialty and state medical societies that...
Continue reading
Topics:
AMA

Florida Law Lowers Opioid Use for Acute Post-Op Pain

  A new controlled substance law in Florida has helped to decrease opioid prescriptions after outpatient surgery, according to a retrospective analysis at a large academic center. Full story.  
Topics:

Oregon Panel Drops Effort to Cut Opioids and Cover Chronic Pain

An Oregon committee has abandoned a controversial proposal that would have expanded treatment options for chronic pain patients under the Oregon Health Plan, but would have forced many to reduce dosages or discontinue pr...
Continue reading

Comparative Effectiveness of Analgesics to Reduce Acute Pain in the Prehospital Setting Report

The Evidence-based Practice Center (EPC) Program at the Agency for Healthcare Research and Quality (AHRQ) has posted the draft report for the systematic review on Comparative Effectiveness of Analgesics to Reduce Acute P...
Continue reading
Topics:

Patient-Centered Care Is Key to Best Practices in Pain Management

Vanila M. Singh, MD MACM, Chairperson of the HHS Pain Management Inter-Agency Task Force, is interviewed about the task force's recommendations for treating acute and chronic pain. Full story.
Topics:
HHS

Oregon Panel Drops Effort to Cut Opioids and Cover Chronic Pain

An Oregon committee has abandoned a controversial proposal that would have expanded treatment options for chronic pain patients under the Oregon Health Plan, but would have forced many to reduce dosages or discontinue prescription opioids. 

Continue reading

AAMC Statement on House Bill to Support New Residency Positions, Including for Pain Management

Association of American Medical Colleges President and CEO Darrell G. Kirch, MD, issued a statement about the Opioid Workforce Act of 2019 (H.R. 2439), which was introduced in the U.S. House of Representatives and would support new addiction medicine, addiction psychiatry, or pain management residency positions. 

Continue reading

FDA Announces Public Meeting to Discuss Safety and Utility of Higher-Dose Opioid Analgesics

FDA is seeking public input on the clinical utility and safety concerns associated with the higher range of opioid analgesic dosing (both in terms of higher strength products and higher daily doses) in the outpatient set...
Continue reading
Topics:

FDA MedWatch Safety Alert: Ketorolac Tromethamine Injection by Sagent Pharmaceuticals: Recall - Due to Lack of Sterility Assurance

Sagent Pharmaceuticals, announced the voluntary nationwide recall of Lot Number M813513 of Ketorolac Tromethamine Injection, USP, 60mg/2mL (30mg per mL). This product was manufactured by Zydus (Cadila Healthcare Limited) and distributed by Sagent Pharmaceuticals, Inc. Sagent has initiated this voluntary recall of Ketorolac Tromethamine Injection, USP to the to the user level due to microbial growth detected during a routine simulation of the manufacturing process, which represents the potential introduction of microorganisms into the products.  

Continue reading

Want more pain resources? Check out our library of on-demand education, upcoming events, and more.

Learn More